YS 49 manufacturers
- YS-49
-
- $41.00 / 1mg
-
2026-04-13
- CAS:132836-42-1
- Min. Order:
- Purity: 99.65%
- Supply Ability: 10g
- YS-49
-
- $41.00 / 1mg
-
2026-04-13
- CAS:132836-42-1
- Min. Order:
- Purity: 99.65%
- Supply Ability: 10g
|
| Product Name: | YS 49 | | Synonyms: | YS 49;1,2,3,4-Tetrahydro-1-(1-naphthalenylmethyl)-6,7-Isoquinolinediol hydrobromide monohydrate;1,2,3,4-Tetrahydro-1-(1-naphthalenylmethyl)-6,7-isoquinolinediol hydrobromide;CS-884;YS 49;YS49;inhibit,YS-49,PI3K,Adrenergic Receptor,Phosphoinositide 3-kinase,PKB,Beta Receptor,YS 49,Akt,Protein kinase B,Inhibitor,YS49,Angiotensin Receptor;YS-49, 10 mM in DMSO;1-(Naphthalen-1-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol hydrobromide | | CAS: | 132836-42-1 | | MF: | C20H20BrNO2 | | MW: | 386.2823 | | EINECS: | | | Product Categories: | Akt;mTOR;PI3K;PI3K/Akt/mTOR | | Mol File: | 132836-42-1.mol |  |
| | YS 49 Chemical Properties |
| storage temp. | 2-8°C | | solubility | H2O: >10mg/mL | | form | solid | | color | White to off-white | | Water Solubility | H2O: >10mg/mL | | InChI | 1S/C20H19NO2.BrH.H2O/c22-19-11-15-8-9-21-18(17(15)12-20(19)23)10-14-6-3-5-13-4-1-2-7-16(13)14;;/h1-7,11-12,18,21-23H,8-10H2;1H;1H2 | | InChIKey | QHCUNMLYODPTIU-UHFFFAOYSA-N | | SMILES | O.Br.Oc1cc2CCNC(Cc3cccc4ccccc34)c2cc1O |
| Hazard Codes | Xn,N | | Risk Statements | 22-50 | | Safety Statements | 61 | | RIDADR | UN 3077 9 / PGIII | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | YS 49 Usage And Synthesis |
| Biological Activity | YS-49 is an activator of PI3K/Akt, a downstream target of RhoA, and reduces RhoA/PTEN activation in 3-methylcholine-treated cells. YS-49 inhibits angiotensin II (Ang II)-stimulated VSMC proliferation by inducing heme oxygenase (HO-1). YS-49 is an isoquinoline compound alkaloid with strong positive inotropic effects due to its ability to activate cardiac β-adrenoceptors. | | in vitro | YS-49 (1-100 μM; 18 hours; RAVSMC and RAW 264.7 cells) concentration-dependently inhibits the accumulation of nitrite in both RAVSMC and RAW 264.7 exposed to lipopolysaccharide (LPS) plus INF-γ, with IC 50 values of 22 μM and 30 μM, respectively.
YS-49 (10-100 μM; 18 hours; RAVSMC and RAW 264.7 cells) suppresses iNOS gene expression induced by LPS and/or cytokines in RAVSMC and RAW 264.7 cells at the transcriptional level. Cell Viability Assay | Cell Line: | RAVSMC and RAW 264.7 cells | | Concentration: | 10 μM, 30 μM and 100 μM (RAVSMC cells); 1 μM, 10 μM and 100 μM (RAW 264.7 cells) | | Incubation Time: | 18 hours | | Result: | Inhibited the accumulation of nitrite in both RAVSMC and RAW 264.7 exposed to LPS+INF-γ, with IC 50 values of 22 and 30 μM, respectively . | Western Blot Analysis | Cell Line: | RAVSMC and RAW 264.7 cells | | Concentration: | 10 μΜ, 30 μΜ and 100 μΜ | | Incubation Time: | 18 hours | | Result: | Concentration -dependently inhibited the expression of iNOS protein induced by LPS plus IFN-γ. | | | in vivo | YS-49 (5 mg/kg; intraperitoneal injection; 8 hours; male Sprague Dawley rats) treatment significantly reduces serum NOx levels in LPS-treated rats, the NOx levels reduce from 86 μM to 34 μM. < /p> < tr> | Animal Model: | Male Sprague Dawley rats (250-300 g) | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneal injection; 8 hours | | Result: | Serum NOx levels were significantly reduced. | |
| | YS 49 Preparation Products And Raw materials |
|